Xerion Healthcare

Name

Xerion Healthcare

Website

https://xerionhealthcare.co.uk

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Nanotechnology (541713), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Neuro-Oncology (HLAKAFAH), Radiation Oncology (HLAKAFAC)

Keywords

• Nanoparticle radiotherapy
• Brain tumor therapy
• Glioblastoma treatment
• Oncology therapeutics
• Radiotherapy enhancement

Headquarters

HQ city

Thame

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

Xerion Healthcare is developing a proprietary nanoparticle solution designed to enhance the effectiveness of post-surgical radiotherapy for aggressive brain tumours, with a primary focus on glioblastoma. The therapy is intended to reduce tumour regrowth and improve patient outcomes and is currently being tested in advanced preclinical models to prepare for clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Nanoparticle Solution for Post-Surgical Radiotherapy

Quantifiable outcome

• Reduction in tumour regrowth for aggressive brain tumours including glioblastoma

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Medicines Discovery Catapult (MDC)coreStrategic or Co-development Partner · 3 November 2022Medicines Discovery Catapult (MDC) and Xerion Healthcare are collaborating on a project funded by Innovate UK to develop a nanoparticle solution for post-surgical radiotherapy. The partnership involves testing nanoparticles in advanced models to demonstrate efficacy and prepare for clinical trials. This addresses a significant unmet need in oncology, especially for glioblastoma, with the potential to advance treatment options.

Direct peers

• Nanobiotix: French clinical-stage biotech developing NBTXR3, a hafnium oxide nanoparticle radio-enhancer injected into tumours to amplify radiotherapy efficacy; the closest direct comparable to Xerion's nanoparticle radio-enhancement approach, including in head & neck and other solid tumours.
• MagForce Nanotechnologies: Germany-listed company commercializing NanoTherm, an iron-oxide nanoparticle therapy for glioblastoma that combines intra-tumoural deposition with hyperthermia; a direct peer because it targets the same indication with a nanoparticle-based physical mechanism intended to enhance tumour cell killing.

Emerging players

• Kazia Therapeutics: Australia-listed oncology biotech whose lead asset paxalisib was specifically developed for glioblastoma (the same indication as Xerion's programme), making it a relevant comparable in terms of indication focus and clinical-development pathway.
• Diffusion Pharmaceuticals: US clinical-stage biotech developing trans sodium crocetinate (TSC) to enhance oxygen delivery to tumours and thereby potentiate radiotherapy; comparable as a small-cap, pre-commercial company developing a radio-sensitizing mechanism for solid tumours.
• Northwest Biotherapeutics: Clinical-stage immuno-oncology company with DCVax-L, an autologous dendritic-cell therapy that has been investigated in newly diagnosed and recurrent glioblastoma; relevant comparable for the glioblastoma indication and small-cap brain-tumour development risk profile.
• Onxeo: European clinical-stage oncology company with DNA-targeting and radio-sensitizing programmes (including AsiDNA for combination with radiotherapy); comparable as a small-cap European biotech developing tumour radio-sensitization mechanisms.
• Phosplatin Therapeutics: US clinical-stage company developing platin-based nanoparticle and small-molecule therapies, including programmes that combine with radiation in solid tumours; comparable as a nanoparticle-format oncology drug developer overlapping with radiotherapy combination strategies.

Broad incumbents

• Novocure: Commercial-stage company marketing Tumor Treating Fields (Optune) as a post-surgical standard of care alongside temozolomide in newly diagnosed glioblastoma; relevant as the dominant incumbent in the indication Xerion is targeting and as a benchmark for the post-surgical GBM market.

Market position

Customer concentration

• LinkedInlinkedin.com/company/xerion-healthcare-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xerion Healthcare